Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2YQK8)

• Drug Name: AR-301 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ventilator-associated pneumonia	PK81.0	Phase 3	[1]
Hospital-acquired pneumonia	CA40.Z	Phase 2	[2]
Pneumonia	CA40	Phase 1/2	[3]

• Cross-matching ID: TTD Drug ID: DM2YQK8

Molecule-Related Drug Atlas

Drug(s) Targeting Staphylococcus Alpha-hemolysin (Stap-coc hly)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cyrtominetin	DM0JA9N	Phlegmy cough	SA80-SA8Z	Phase 3	[5]
MEDI4893	DMXB4NL	Ventilator-associated pneumonia	PK81.0	Phase 2b	[6]
ASN100	DMWPGLS	Hospital-acquired pneumonia	CA40.Z	Phase 2	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus Alpha-hemolysin (Stap-coc hly)	TT5FLYB	HLA_STAAU	Inhibitor	[4]

References

• [1] ClinicalTrials.gov (NCT03816956) Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 (AR-301-002). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT01589185) Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus). U.S. National Institutes of Health.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036003)
• [4] Clinical pipeline report, company report or official report of Aridis Pharmaceuticals.
• [5] Molecular insight into the inhibition mechanism of cyrtominetin to alpha-hemolysin by molecular dynamics simulation. Eur J Med Chem. 2013 Apr;62:320-8.
• [6] Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80.
• [7] Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8.